Opportunity Information: Apply for PAR 06 171
Apply for PAR 06 171
- The National Institutes of Health in the education food and nutrition health sector is offering a public funding opportunity titled "Endoscopic Clinical Research In Pancreatic And Biliary Diseases (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Mar 2, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: County governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Independent school districts City or township governments Private institutions of higher education State governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Endoscopic Clinical Research in Pancreatic and Biliary Diseases (R03)" (Funding Opportunity Number PAR 06 171) supports small, early-stage clinical and epidemiological studies focused on ERCP (Endoscopic Retrograde Cholangiopancreatography) and related endoscopic or imaging approaches used to diagnose and treat pancreatic and biliary disorders. It is jointly encouraged by the Division of Digestive Diseases and Nutrition (DDDN) within NIDDK and the Division of Cancer Prevention within NCI, reflecting an emphasis on both digestive disease outcomes and cancer prevention or early detection implications where relevant.
The central problem this announcement is trying to address is the gap between widespread real-world use of advanced endoscopic and imaging technologies and the limited amount of strong evidence from rigorous clinical trials that clearly guides when and how these technologies should be used. Pancreatic and biliary diseases create a major burden in the United States, contributing to substantial illness, deaths, and health care spending. The announcement highlights a broad spectrum of conditions where ERCP and other tools may play a role, including pancreatic cancers (exocrine and endocrine), gallstone-related disease (including sludge), pancreatic and biliary malignancies, traumatic injury, congenital or structural abnormalities such as pancreas divisum, alcohol- and drug-associated disease, and difficult idiopathic syndromes such as idiopathic pancreatitis and sphincter of Oddi dysfunction. The NIH State of the Science Conference on ERCP is specifically referenced as concluding that, despite heavy clinical adoption, the evidence base has not kept pace with clinical practice.
This mechanism uses the NIH R03 small grant format to fund work that is intentionally limited in scope but strategically designed to lead to larger, definitive projects. In practice, the R03 funds are meant to function as either planning grants for future full-scale, multi-center clinical trials or as pilot studies that generate preliminary data needed to justify and design those larger trials. A key theme is that the resulting research should be capable of informing whether current standards of care should change, meaning projects should aim to produce actionable evidence for or against specific clinical practices, diagnostic pathways, or therapeutic interventions involving ERCP and other advanced endoscopic or imaging techniques.
In addition to clinical pilots, the announcement encourages pilot epidemiological studies. These are intended to seed more extensive research that could ultimately support evidence-based changes in health policy, particularly policies tied to disease prevention and cancer prevention. That emphasis suggests interest in studies that clarify who benefits most from certain procedures, how to reduce procedure-related harms, how technologies perform in real-world populations, and how patterns of use relate to outcomes across health systems or demographic groups.
The announcement also makes clear that these R03 awards are expected to serve as stepping stones toward larger NIH applications, especially multi-center research project grants (R01) or cooperative agreements (U01). In other words, applicants are expected to propose work that can mature into broader collaborations and more definitive trials once feasibility, recruitment, measurement strategies, endpoints, and preliminary effect sizes are better established.
Applicants can include both new and experienced investigators across relevant disciplines, and the announcement explicitly positions the R03 as a helpful entry point for investigators looking to build capability in clinical and epidemiological research. It also encourages applicants to leverage recent developments in endoscopic practice and laboratory science, implying that proposals incorporating newer tools, improved imaging, evolving endoscopic techniques, biomarker work, or modern trial and observational study methods would be responsive as long as they directly address clinically meaningful questions in pancreatic and biliary disease.
Administratively, this is a discretionary grant program (not a cost-sharing program; no matching funds required) with an award ceiling listed as $50,000. The opportunity had multiple receipt dates (rather than a single deadline), and it was originally posted March 2, 2006, with an archive date of June 1, 2009, indicating it is an older, archived opportunity rather than an actively open announcement today. The CFDA numbers referenced include 93.395 (Cancer Treatment Research). A wide range of applicant organizations were eligible, including public and private higher education institutions, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses), state and local government entities, tribal governments and tribal organizations, public housing authorities, independent school districts, special district governments, and other entities as described in the full announcement. Foreign institutions were eligible to apply, and eligible federal agencies could also apply, which signals NIH interest in broad participation and potentially international collaboration when scientifically justified.
Overall, the opportunity is best understood as targeted seed funding meant to strengthen the evidence base around ERCP and related endoscopic/imaging approaches in pancreatic and biliary disease. It prioritizes feasibility work, early clinical trials, and pilot epidemiology that can credibly lead to larger multi-center efforts capable of changing clinical guidelines, standard care practices, or prevention-related health policies.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Endoscopic Clinical Research in Pancreatic and Biliary Diseases (R03)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR 06 171.
What type of grant mechanism does this opportunity use?
This opportunity uses the NIH R03 small grant mechanism, which is designed for projects that are intentionally limited in scope but positioned to lead to larger, definitive studies later.
What is the main purpose of this R03 program?
The main purpose is to support small, early-stage clinical and epidemiological studies focused on ERCP and related endoscopic or imaging approaches in pancreatic and biliary diseases, with the goal of strengthening the clinical evidence base and enabling larger future trials or multi-center studies.
What problem is NIH trying to address with this announcement?
The announcement targets the gap between widespread real-world use of advanced endoscopic and imaging technologies and the limited amount of strong evidence from rigorous clinical trials that clearly guides when and how these technologies should be used.
What procedures or technologies are emphasized?
The announcement emphasizes ERCP (Endoscopic Retrograde Cholangiopancreatography) and also includes related endoscopic and imaging approaches used to diagnose and treat pancreatic and biliary disorders.
Which NIH components are encouraging this program?
The program is jointly encouraged by the Division of Digestive Diseases and Nutrition (DDDN) within NIDDK and the Division of Cancer Prevention within NCI.
Why is there an emphasis on both digestive disease outcomes and cancer prevention?
The involvement of NIDDK and NCI reflects an interest in research that improves outcomes in pancreatic and biliary disease while also considering cancer prevention or early detection implications where relevant.
What kinds of studies are considered responsive?
Responsive projects include small, early-stage clinical studies and pilot epidemiological studies focused on clinically meaningful questions about the use of ERCP and related endoscopic/imaging tools in pancreatic and biliary disorders.
Is this funding intended for large, definitive clinical trials?
No. This R03 mechanism is intended for limited-scope work, such as planning and feasibility efforts or pilot studies that generate preliminary data needed to design and justify larger, definitive trials.
How are the R03 funds expected to be used in practice?
The funds are meant to function as planning grants for future full-scale (often multi-center) clinical trials or as pilot studies that provide preliminary data on feasibility, recruitment, measurement approaches, endpoints, and early estimates of effect sizes.
What larger grant types does NIH expect these R03 projects to lead to?
The announcement states that R03 awards are expected to serve as stepping stones toward larger NIH applications, especially multi-center research project grants (R01) or cooperative agreements (U01).
What diseases and clinical areas are within scope?
The scope includes a broad range of pancreatic and biliary conditions where ERCP or related approaches may be used, including pancreatic cancers (exocrine and endocrine), gallstone-related disease (including sludge), pancreatic and biliary malignancies, traumatic injury, congenital or structural abnormalities (such as pancreas divisum), alcohol- and drug-associated disease, and difficult idiopathic syndromes such as idiopathic pancreatitis and sphincter of Oddi dysfunction.
Does the opportunity mention any prior NIH conclusions or background reports?
Yes. It references the NIH State of the Science Conference on ERCP, which concluded that despite heavy clinical adoption, the evidence base has not kept pace with clinical practice.
What makes a project a good fit for this program?
A good fit is a project that can produce actionable evidence for or against specific clinical practices, diagnostic pathways, or therapeutic interventions involving ERCP and related endoscopic or imaging techniques, and that is credibly positioned to mature into a larger multi-center study.
Are epidemiological studies encouraged, or is this only for clinical pilots?
Pilot epidemiological studies are explicitly encouraged in addition to clinical pilot studies.
What is the purpose of encouraging pilot epidemiological studies?
The purpose is to seed more extensive research that could ultimately support evidence-based changes in health policy, particularly policies tied to disease prevention and cancer prevention.
What kinds of epidemiological questions appear relevant based on the announcement?
The announcement highlights interest in studies that clarify who benefits most from certain procedures, how to reduce procedure-related harms, how technologies perform in real-world populations, and how patterns of use relate to outcomes across health systems or demographic groups.
Does the program require matching funds or cost sharing?
No. The program is described as discretionary and specifically notes that it is not a cost-sharing program and does not require matching funds.
What is the award ceiling for this opportunity?
The award ceiling is listed as $50,000.
Were there multiple deadlines to apply?
Yes. The opportunity had multiple receipt dates rather than a single deadline.
Is this opportunity currently active?
Based on the information provided, it appears to be an older, archived opportunity: it was originally posted on March 2, 2006, and has an archive date of June 1, 2009.
What is the CFDA number associated with this opportunity?
The CFDA number referenced includes 93.395 (Cancer Treatment Research).
Who is eligible to apply?
A wide range of organizations were eligible, including public and private higher education institutions, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses), state and local government entities, tribal governments and tribal organizations, public housing authorities, independent school districts, special district governments, and other entities as described in the full announcement.
Are foreign institutions eligible to apply?
Yes. Foreign institutions were eligible to apply.
Can federal agencies apply?
Yes. Eligible federal agencies could also apply, indicating broad participation was allowed under this announcement.
Does this opportunity encourage participation from early-career or new investigators?
Yes. The announcement indicates applicants can include both new and experienced investigators across relevant disciplines and frames the R03 as a helpful entry point for investigators building capability in clinical and epidemiological research.
Does the announcement encourage use of newer tools or methods?
Yes. It encourages applicants to leverage recent developments in endoscopic practice and laboratory science, including newer tools, improved imaging, evolving endoscopic techniques, biomarker work, or modern trial and observational study methods, as long as they directly address clinically meaningful questions in pancreatic and biliary disease.
What is the overall takeaway about what NIH wanted to fund here?
Overall, this opportunity is targeted seed funding meant to strengthen the evidence base around ERCP and related endoscopic/imaging approaches in pancreatic and biliary disease by supporting feasibility work, early clinical trials, and pilot epidemiology that can lead to larger multi-center efforts capable of changing clinical guidelines, standards of care, or prevention-related health policies.
Browse more opportunities from the same category: Education Food and Nutrition Health
Next opportunity: Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure (R21)
Previous opportunity: Improving Diet and Physical Activity Assessment (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 06 171
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 06 171) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 06 256 Funding Number: PA 06 256 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R21) Apply for PA 06 413 Funding Number: PA 06 413 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R03) Apply for PA 06 414 Funding Number: PA 06 414 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $50,000 |
| Mechanisms of Alcohol and Drug InducedPancreatitis (R01) Apply for PA 07 067 Funding Number: PA 07 067 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Diet, Epigenetic Events, and Cancer Prevention (R01) Apply for PA 07 175 Funding Number: PA 07 175 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R01) Apply for PA 07 301 Funding Number: PA 07 301 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R21) Apply for PA 07 302 Funding Number: PA 07 302 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Development of Assays for High Throughput Drug Screening (R01) Apply for PA 07 320 Funding Number: PA 07 320 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Research on the Economics of Diet, Activity, and Energy Balance (R01) Apply for PA 08 078 Funding Number: PA 08 078 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R01) Apply for PA 08 083 Funding Number: PA 08 083 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) Apply for PA 08 243 Funding Number: PA 08 243 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Brain and Behavioral Research (SBIR R43/R44) Apply for PA 08 071 Funding Number: PA 08 071 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Biomedical and Behavioral Research (SBIR R43/R44) Apply for PA 08 114 Funding Number: PA 08 114 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 09 124 Funding Number: PA 09 124 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Biobehavioral Methods to Improve Outcomes Research (R01) Apply for PA 09 125 Funding Number: PA 09 125 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Pilot and Feasibility Clinical Research Studies in Digestive Diseases and Nutrition (R21) Apply for PA 09 151 Funding Number: PA 09 151 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Development and Validation of Disease Biomarkers (R01) Apply for PA 09 204 Funding Number: PA 09 204 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Health Disparities in NIDDK Diseases (R01) Apply for PA 09 262 Funding Number: PA 09 262 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Development of Assays for High Throughput screening for use in Probe and Pre therapeutic Discovery (R01) Apply for PA 10 213 Funding Number: PA 10 213 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Health Promotion Among Racial and Ethnic Minority Males (R01) Apply for PA 10 236 Funding Number: PA 10 236 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 06 171", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.